Erasca, Inc. (NASDAQ:ERAS) Given Average Recommendation of “Moderate Buy” by Analysts

Erasca, Inc. (NASDAQ:ERAS) has been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $18.75.

A number of analysts have recently weighed in on the stock. Mizuho reduced their target price on shares of Erasca from $28.00 to $26.00 and set an “outperform” rating on the stock in a report on Tuesday. Piper Sandler boosted their target price on shares of Erasca from $11.00 to $18.00 and gave the stock an “overweight” rating in a report on Friday, March 13th. HC Wainwright boosted their target price on shares of Erasca from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, March 13th. JPMorgan Chase & Co. boosted their target price on shares of Erasca from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, March 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Erasca in a report on Thursday, January 22nd.

Erasca Stock Down 0.6%

ERAS stock opened at $10.38 on Wednesday. Erasca has a 52 week low of $1.06 and a 52 week high of $24.28. The company has a fifty day simple moving average of $15.49 and a two-hundred day simple moving average of $9.46. The firm has a market capitalization of $3.23 billion, a P/E ratio of -11.16 and a beta of 0.68.

Erasca (NASDAQ:ERAS) last posted its earnings results on Monday, May 11th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.50). As a group, analysts anticipate that Erasca will post -0.51 EPS for the current year.

Insider Transactions at Erasca

In other Erasca news, insider Ebun Garner sold 80,000 shares of the business’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $16.40, for a total transaction of $1,312,000.00. Following the transaction, the insider owned 25,076 shares in the company, valued at $411,246.40. The trade was a 76.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Morris sold 20,000 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $15.04, for a total transaction of $300,800.00. The SEC filing for this sale provides additional information. Insiders own 14.20% of the company’s stock.

Institutional Investors Weigh In On Erasca

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Baader Bank Aktiengesellschaft purchased a new stake in shares of Erasca in the first quarter valued at $291,000. Dimensional Fund Advisors LP grew its holdings in shares of Erasca by 0.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,786,389 shares of the company’s stock worth $28,873,000 after purchasing an additional 10,704 shares during the last quarter. KBC Group NV purchased a new stake in Erasca in the first quarter worth about $81,000. Swiss National Bank purchased a new stake in Erasca in the first quarter worth about $5,449,000. Finally, Marks Group Wealth Management Inc purchased a new stake in Erasca in the first quarter worth about $483,000. Hedge funds and other institutional investors own 67.78% of the company’s stock.

Key Headlines Impacting Erasca

Here are the key news stories impacting Erasca this week:

• Positive Sentiment: Erasca announced a clinical trial collaboration and supply agreement with Merck to evaluate ERAS-0015 in combination with KEYTRUDA, a partnership that could validate its lead RAS-targeting program and expand the drug’s commercial potential. Article: Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA (Pembrolizumab)
• Positive Sentiment: Mizuho kept an outperform rating and trimmed its price target only slightly to $26 from $28, signaling continued bullish analyst sentiment despite the recent pullback. Article: Erasca price target lowered by Mizuho
• Neutral Sentiment: Erasca’s first-quarter update highlighted robust early clinical data for ERAS-0015, including monotherapy efficacy and generally well-tolerated safety, which supports the company’s pipeline story but is still early-stage development. Article: Erasca Reports First Quarter 2026 Business Updates and Financial Results
• Neutral Sentiment: A Seeking Alpha note initiated coverage with a Hold rating, citing promising ERAS-0015 data but also safety and patent-litigation risks that could limit upside until more evidence emerges. Article: Erasca: ‘Hold’ On Substantial RAS Targeting ERAS-0015 But With Two Key Risks
• Negative Sentiment: Pomerantz and Schall both disclosed shareholder investigations into Erasca, adding legal uncertainty and potentially pressuring the stock as investors assess possible securities-law claims. Article: INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. – ERAS
• Negative Sentiment: The company’s quarterly earnings missed expectations by a wide margin, reinforcing concerns about ongoing losses and the near-term financial picture. Article: Erasca earnings data and stock report

About Erasca

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.